Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L., Department of Neurochemistry, Institute of Neurology, University College London, UK. Nature. 2000 Mar 2;404(6773):84-7.

Modulation of presynaptic inhibition and disynaptic reciprocal Ia inhibition during voluntary movement in spasticity.

Morita H, Crone C, Christenhuis D, Petersen NT, Nielsen JB., Division of Neurophysiology, Department of Medical Physiology, The Panum Institute, Copenhagen University, Blegdamsvej, Copenhagen, Denmark. Brain. 2001 Apr;124(Pt 4):826-37.

Rehabilitation of patients with multiple sclerosis.

Mayer M, Bazala J, Muchova B, Stranska H., Oddeleni medicinske rehabilitace FN, Olomouc., Brain. 2001 Apr;124(Pt 4):826-37.

Medical marijuana: legal considerations.

Schouten JT., STEP Perspect. 1999 Summer;99(2):5. No abstract available.

Comment on 'Health aspects of cannabis: revisited' (Hollister).

Johnson BA., Clinical Laboratory and Experimental Alcohol Research Center, Houston Health Science Center, University of Texas-Houston, TX USA. Int J Neuropsychopharmcol. 1998 Jul;1(1):81-82.

Potential therapeutic usefulness of cannabis and cannabinoids].

Lorenzo Fernandez P. An R Acad Nac Med (Madr). 2000;117(3):595-605; discussion 616-24. Review. Spanish.

Endocannabinoids control spasticity in a multiple sclerosis model.

Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V. Neuroinflammation Group, Institute of Neurology, University College London, UK. FASEB J. 2001 Feb;15(2):300-2.

Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin.

Vogt T, Urban PP., Klinik und Poliklinik fur Neurologie der Johannes Gutenberg Universitat., Nervenarzt. 2000 Dec;71(12):1007-11. German.

CLINICAL CORRESPONDENCE: the effect of magnesium oral therapy on spasticity in a patient with multiple sclerosis.

Rossier P, van Erven S, Wade DT., Rivermead Rehabilitation Centre, Abingdon Road, Oxford OX1 4XD, UK, Eur J Neurol. 2000 Nov;7(6):741-4.

Anti-spasticity agents for multiple sclerosis (Cochrane Review).

Shakespeare DT, Young CA, Boggild M., The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, UK, Cochrane Database Syst Rev. 2000;(4):CD001332.

Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis

Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study.
Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P, Glickman S, Sayer A, Richardson A, Dott C., Radcliffe Infirmary, Oxford, UK. J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):707-12.

Effect of cooling suit treatment in patients with multiple sclerosis evaluated by evoked potentials.

Kinnman J, Andersson T, Andersson G., Department of Neurology, Lanssjukhuset Halmstad, Sweden. Scand J Rehabil Med. 2000 Mar;32(1):16-9.

Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients.

Nielsen JF, Anderson JB, Sinkjaer T., Center for Sensory-Motor Interaction, Department of Medical Informatics and Image Analysis, Aalborg University, Denmark. Mult Scler. 2000 Apr;6(2):105-14.

Effect of baclofen on gait in spastic MS patients.

Orsnes GB, Sorensen PS, Larsen TK, Ravnborg M., Department of Neurology, Rigshospitalet, Copenhagen, Denmark. Acta Neurol Scand. 2000 Apr;101(4):244-8.

Cannabinoids control spasticity and tremor in a multiple sclerosis model.

University College London, UK. Nature. 2000 Mar 2;404(6773):84-7.

Long-term intrathecal (i.t.) infusion of bupivacaine relieved intractable pain and spasticity in a patient with multiple sclerosis.

Dahm PO, Nitescu PV, Appelgren LK, Curelaru I I., Department of Anaesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden Eur J Pain. 1998 Mar;2(1):81-85.